List view / Grid view
28 May 2015 | By Victoria White
Pfizer has announced initial results of its global NarRAtive survey of more than 3,600 adults with rheumatoid arthritis in 13 countries...
12 May 2015 | By Victoria White
Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company...
22 April 2015 | By Victoria White
Pfizer’s XALKORI has received Breakthrough Therapy designation from the FDA for the potential treatment of patients with ROS1-positive NSCLC...
21 April 2015 | By Victoria White
Pfizer Phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)...
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
15 April 2015 | By Victoria White
The Phase 3 PALOMA-3 trial for IBRANCE has been stopped early due to efficacy seen in women with HR+, HER2- metastatic breast cancer...
25 March 2015 | By Victoria White
Pfizer Inc. and Eli Lilly and Company have announced that they are preparing to resume the Phase 3 clinical programme for tanezumab...
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
9 February 2015 | By GlobalData
Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, says: “On 5 February 2015, just days after gaining US Food and Drug Administration (FDA) breakthrough approval for Ibrance (palbociclib) in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira..."
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...
Michael J. Miller discusses rapid microbiological methods and the regulatory environment, the Online Water Bioburden Analyzer Workgroup look at the path to implementing Online Water Bioburden Analyzers, plus RMM roundtable...
Sulaf Assi discusses the investigation of medicine quality using handheld Raman spectroscopy, a look at Raman hyperspectral imaging, plus Raman roundtable...
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States regulatory approval from all government authorities required by the agreement and other closing conditions...
29 August 2014 | By Pfizer
...for intravenous use for the treatment of type 1 Gaucher disease.
